Psilocybin to Psilocin: The Pharmacokinetics of a Prodrug

Psilocybin is inactive until the body converts it to psilocin. How that conversion works, how psilocin is absorbed, distributed, and cleared, why its short half-life shapes the practice of microdosing, and why dose-by-weight is an imperfect proxy for what reaches the brain.

Published June 4, 2026 · Reviewed June 4, 2026 · Research & Editorial Team

Peer-reviewed: 7 · Total: 7 · 10 min read

TL;DR

The molecule people take is not the molecule that acts. Psilocybin is a prodrug — biologically inactive until the body strips a phosphate group from it, principally by the enzyme alkaline phosphatase, to produce psilocin. Psilocin is what crosses into the brain, engages serotonin receptors, and is then cleared comparatively quickly, with a half-life of a few hours and a single full-dose effect lasting around four to six hours. This pharmacokinetic profile is well characterized at psychoactive doses, and it explains two practical features of microdosing: why the practice uses repeated scheduled dosing rather than one exposure, and why dose-by-weight is only a rough guide to what actually reaches the brain. At sub-perceptual doses, the same pathway applies but the precise numbers are far less certain.

Why “psilocybin” is the wrong name for the active compound

In everyday language, psilocybin is the drug. Pharmacologically, that is not quite right. Psilocybin has limited direct psychoactive activity of its own and functions primarily as a prodrug — a precursor the body must convert before much happens. Within a short time of ingestion, the molecule is dephosphorylated — a phosphate group is enzymatically removed, mainly by alkaline phosphatase, with non-specific esterases also contributing — yielding psilocin, the compound responsible for the central effects. [1] This conversion happens largely in the gut and on first pass through the body, and in practice psilocybin itself is barely detectable in plasma; what circulates and acts is psilocin. [2]

The ADME pathway

Pharmacokinetics is conventionally summarized in four stages — absorption, distribution, metabolism, and excretion, abbreviated ADME — describing what the body does to a compound from intake to elimination. Psilocybin follows this sequence with one twist at the front: it is absorbed and almost immediately converted to psilocin, which is then distributed to target tissues including the brain, metabolized in the liver, and excreted. [1] The sections below walk through that path and, at each stage, mark where the numbers are well established and where they are not.

Two consequences follow immediately. First, the delay between taking a dose and feeling anything reflects this conversion step rather than slow receptor action — the body has to make the active drug first. Second, every claim about “psilocybin’s mechanism” is really a claim about psilocin, which is why the 5-HT2A mechanism article is framed around psilocin rather than psilocybin.

Absorption and distribution

Once formed, psilocin is absorbed and distributed through the body. It is sufficiently lipophilic to cross the blood–brain barrier and reach the cortical sites where 5-HT2A receptors are concentrated, which is what allows an orally taken mushroom to produce central effects. [3] Human pharmacokinetic work, beginning with the classic studies of oral and intravenous psilocybin, established the basic time course: psilocin appears in plasma within the first part of an hour, rises to a peak, and then declines. [2] The exact timing varies with formulation, digestion, individual metabolism, and study conditions, so these figures describe a typical profile rather than a fixed schedule. [4] Controlled modern dosing studies in healthy adults have since mapped this across a range of escalating oral doses, characterizing how plasma exposure scales with the amount taken. [4]

The reason this time course matters beyond bookkeeping is that plasma psilocin is tied to the effect. Imaging work has shown that the concentration of psilocin in the blood tracks both the degree of 5-HT2A receptor occupancy in the brain and the intensity of the subjective experience. [5] This is the place to draw a distinction the rest of the cluster relies on. Pharmacokinetics describes how much compound reaches the body and when; pharmacodynamics describes what the compound does once it reaches its biological targets. Higher exposure increases the opportunity for receptor engagement, but the biological response still depends on receptor activity, downstream signalling, and individual sensitivity — so exposure and effect are related but not identical.

Metabolism and clearance

Psilocin does not linger. It is cleared through further metabolism, prominently by conjugation in the liver — glucuronidation, which produces psilocin-O-glucuronide, the main metabolite recovered in urine — with oxidative routes and monoamine oxidase also contributing to its breakdown. [1] Human studies place psilocin’s elimination half-life in the range of roughly one and a half to three hours, and the subjective effects of a full dose typically resolve within about four to six hours. [2] [6] Excretion studies have characterized how psilocin and its metabolites are eliminated, largely via the kidneys, over the following day. [6]

This short pharmacokinetic life has a direct bearing on how microdosing is practised. Because a dose is metabolized and gone within hours, any sustained or cumulative effect cannot come from a drug that is continuously present — it would have to come from changes that outlast the drug’s presence. A short plasma presence does not, by itself, rule out longer-lasting biological effects; it simply means that any such effect would have to arise from downstream adaptations rather than from continued exposure to the drug. That is precisely why microdosing is built around a repeating schedule rather than steady exposure, and why the plasticity hypothesis examined in the neuroplasticity and BDNF article is the kind of mechanism that could, in principle, bridge the gap between a transient dose and a lasting change.

Why dose-by-weight is an imperfect proxy

Microdosing guidance often expresses dose relative to body weight or as a fixed quantity of dried mushroom. Pharmacokinetics shows why those figures are approximations rather than precise controls on what the brain receives.

The first source of slippage is the source material. Dried mushrooms vary substantially in psilocybin content between species, between batches, and even within a single specimen, so a given weight of mushroom does not correspond to a fixed amount of psilocybin. [1] This is compounded by the fact that whole mushroom material is not the purified pharmaceutical psilocybin used in most controlled studies: natural material differs in concentration, distribution within the mushroom, and overall composition, adding variability that clinical-grade preparations are specifically designed to remove. [1] The second source is the body. Conversion of psilocybin to psilocin and the subsequent metabolism of psilocin vary between individuals — through differences in enzyme activity, body composition, and biological sensitivity — producing meaningful inter-person differences in how much active psilocin actually circulates from the same nominal dose. [1] The net result is a chain of inequalities: the dose taken is not the dose absorbed, which is not the amount of psilocin reaching the brain. Two people taking the same milligram-per-kilogram dose can reach different plasma psilocin levels — and since plasma psilocin is what tracks the effect, dose-by-weight predicts the outcome only loosely. [5] The dosing thresholds themselves, and what “sub-perceptual” means quantitatively, are treated in what a microdose is.

As with the receptor data, the detailed human pharmacokinetics were obtained at psychoactive doses, where psilocin reaches plasma concentrations high enough to measure reliably. [2] [4] At sub-perceptual doses, concentrations are far lower and correspondingly harder to characterize, so the absorption profile, peak levels, and brain exposure produced by a typical microdose are not mapped with the same confidence. [7] The qualitative pathway is not in doubt — prodrug to psilocin to receptor — but the quantitative picture at microdose levels, including whether a sub-perceptual dose reaches a meaningful brain concentration at all, remains underspecified.

Key concepts

Prodrug: Psilocybin is inactive as taken; the body converts it — mainly via alkaline phosphatase — into psilocin, the active compound. [1]
Plasma psilocin tracks effect: The concentration of psilocin in blood corresponds to receptor occupancy and to the intensity of the experience, linking pharmacokinetics to effect. [5]
Short half-life: Psilocin’s elimination half-life is roughly one and a half to three hours, and a full-dose effect lasts about four to six hours — the drug is gone well before any cumulative change could be measured. [2]
Dose-by-weight is approximate: Variation in mushroom potency and in individual metabolism means a fixed weight-based dose does not reliably produce a fixed brain exposure. [1]

Frequently asked questions

Why is psilocybin called a prodrug?

A prodrug is a compound that is largely inactive as taken and must be converted by the body into the substance that actually does the work. Psilocybin is that inactive form. Soon after ingestion, an enzyme called alkaline phosphatase removes a phosphate group from it, turning it into psilocin, which is the molecule that crosses into the brain and activates serotonin receptors. [1] So when people talk about psilocybin’s effects, the active agent is really psilocin. [2]

How long does psilocin stay in the body?

Not long. Human studies put psilocin’s elimination half-life in the range of roughly one and a half to three hours, and the subjective effects of a full dose typically last about four to six hours before fading. [2] Psilocin is cleared through further metabolism — including conjugation in the liver — and excreted, largely as a metabolite, in urine. [1] [6] Its short presence in the body is one reason microdosing is structured as repeated, scheduled dosing rather than a single exposure.

Does taking more by body weight reliably mean a stronger effect?

Only loosely. Dose scaled to body weight is a starting approximation, not a precise predictor, because how much psilocin actually reaches the brain varies between people and between mushroom batches. [1] Conversion efficiency, individual metabolism, and large differences in the potency of dried mushrooms all add variability, so two people taking the same milligram-per-kilogram dose can end up with quite different plasma psilocin levels — and plasma psilocin is what tracks the effect. [5]

Is the pharmacokinetics of a microdose known?

Much less precisely than for full doses. The detailed human pharmacokinetic studies used psychoactive doses, where psilocin can be measured reliably in plasma. [4] At sub-perceptual doses the concentrations are far lower and far harder to characterize, so the absorption, peak levels, and brain exposure produced by a typical microdose have not been mapped with the same confidence. [7] The general pathway is the same; the specific numbers at microdose levels are not well established.

Does the same amount of mushroom always create the same psilocin level?

No. Mushroom composition, the efficiency of conversion to psilocin, absorption, and metabolism all influence how much psilocin ends up circulating after a given dose. [1] Dried mushrooms also vary in potency between species, batches, and even within one specimen. A measured amount of mushroom is therefore not the same thing as a measured amount of active compound reaching the brain, which is part of why effects vary between people and between doses. [5]

References

[1]

Dinis-Oliveira RJ (2017). Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metabolism Reviews. Peer-reviewed doi:10.1080/03602532.2016.1278228

[2]

Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX (1997). Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharmaceutica Acta Helvetiae. Peer-reviewed doi:10.1016/s0031-6865(97)00014-9

[3]

Nichols DE (2016). Psychedelics. Pharmacological Reviews. Peer-reviewed doi:10.1124/pr.115.011478

[4]

Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR (2017). Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. Clinical Pharmacokinetics. Peer-reviewed doi:10.1007/s40262-017-0540-6

[5]

Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbæk DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. Peer-reviewed doi:10.1038/s41386-019-0324-9

[6]

Hasler F, Bourquin D, Brenneisen R, Vollenweider FX (2002). Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. Journal of Pharmaceutical and Biomedical Analysis. Peer-reviewed doi:10.1016/s0731-7085(02)00278-9

[7]

Kuypers KPC, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D (2019). Microdosing psychedelics: More questions than answers? An overview and suggestions for future research. Journal of Psychopharmacology. Peer-reviewed doi:10.1177/0269881119857204

Last reviewed June 4, 2026 by Research & Editorial Team